G1 Therapeutics Inc Stock News

GTHX earnings call for the period ending December 31, 2021.

GTHX earnings call for the period ending December 31, 2021.

G1 Therapeutics' (GTHX) CEO Jack Bailey on Q4 2021 Results - Earnings Call Transcript

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 8.74% and 6.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

G1 Therapeutics press release (GTHX): Q4 GAAP EPS of -$0.94 beats by $0.09.Revenue of $5.79M (-65.0% Y/Y) beats by $0.07M.Shares +3.63% PM.As of December 31, 2021, cash and

- Achieved $5.8 Million in Total Revenue in the Fourth Quarter of 2021, Including $4.4 Million in Net Revenue from Sales of COSELA™ (trilaciclib) -

- Achieved $5.8 Million in Total Revenue in the Fourth Quarter of 2021, Including $4.4 Million in Net Revenue from Sales of COSELA (trilaciclib) -

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 8.74% and 6.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

G1 Therapeutics (NASDAQ:GTHX) is scheduled to announce Q4 earnings results on Wednesday, February 23rd, before market open.The consensus EPS Estimate is -$1.02 (-52.2% Y/Y) and

RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corpor

RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the fourth quarter and full year 2021 on Wednesday, February 23, 2022 at 8:30 a.m. ET.

Cosela is an FDA-approved myelosuppressive agent given before chemotherapy in patients with extensive-stage small cell lung cancer. Cosela may potentially alter the tumor microenvironment and improve

RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerc

G1 Therapeutics Inc (GTHX) shares closed today at 0.2% above its 52 week low of $9.65, giving the company a market cap of $411M. The stock is currently down 5.3% year-to-date, down 45.0% over the past 12 months, and down 35.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 14.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 1929.5% The company's stock price performance over the past 12 months lags the peer average by 506.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.